# Tirzepatide for Sleep Apnea: What the Research Shows **By TelosRX Editorial Team** · 2026-07-09 **Tirzepatide for sleep apnea is one of the most significant metabolic research developments in recent years — and [TelosRX](https://telosrx.com) breaks down exactly what two landmark clinical trials found, what the data actually supports, and what remains unknown.** Most people know tirzepatide as a weight-loss medication. That framing is accurate — but narrow. Published phase 3 research has now documented a more surprising finding: tirzepatide significantly reduces the severity of obstructive sleep apnea (OSA), with effects that may extend beyond what weight loss alone predicts. Here’s what the science actually shows. ## What Is Obstructive Sleep Apnea? OSA occurs when the upper airway repeatedly collapses during sleep. Each collapse is an apnea event — a partial airway obstruction that disrupts oxygenation and fragments sleep without full awakening. An estimated 1 billion people worldwide have some degree of OSA, and obesity is its strongest modifiable risk factor. Severity is measured by the apnea-hypopnea index (AHI): the number of breathing disruptions per hour. An AHI of 5–14 is mild; 15–29 is moderate; 30+ is severe. Standard treatment is CPAP — continuous positive airway pressure. CPAP works mechanically, but 30–50% of patients struggle with long-term adherence. ## The SURMOUNT-OSA Trials: Study Design Eli Lilly conducted two parallel phase 3 randomized controlled trials — SURMOUNT-OSA 1 and SURMOUNT-OSA 2 — published in the _New England Journal of Medicine_ in June 2024. The trials enrolled adults with moderate-to-severe OSA (AHI ≥15) and obesity (BMI ≥30). Key design points: - SURMOUNT-OSA 1: 234 participants, no current CPAP use - SURMOUNT-OSA 2: 235 participants, ongoing CPAP use - Treatment: tirzepatide weekly injection (up to 10 or 15 mg), titrated over 8–16 weeks - Duration: 52 weeks - Primary endpoint: change in AHI from baseline at 52 weeks The trials were double-blind and placebo-controlled, with randomization stratified by BMI and AHI severity category — a methodologically rigorous design for a chronic disease population. ## Finding 1 — AHI Dropped Significantly in Both Cohorts The headline result: tirzepatide reduced AHI substantially in both trials. Metric SURMOUNT-OSA 1 (No CPAP) SURMOUNT-OSA 2 (With CPAP) Mean AHI reduction (events/hr) −27.4 vs. −4.8 (placebo) −30.4 vs. −6.0 (placebo) Percent AHI reduction ~55% ~62% OSA remission rate (AHI <5) ~42% ~51% Mean body weight reduction ~18.5% ~20.1% Hypoxic burden (min/hr with SpO2 <90%) Significantly reduced Significantly reduced Source: [Malhotra et al., _NEJM_ 2024](https://www.nejm.org/doi/full/10.1056/NEJMoa2404881) These reductions are clinically meaningful. Dropping AHI by 27–30 events per hour can shift a severe case to mild or remission. Nearly half of no-CPAP participants and more than half of CPAP-continuing participants achieved AHI below 5 — the clinical threshold for OSA remission. ## Finding 2 — Weight-Independent Effects May Exist The weight loss was real: participants lost roughly 18–20% of body weight. But here’s the detail that drew attention from sleep medicine researchers: statistical mediator analyses in the SURMOUNT-OSA data suggested that weight loss explained only a portion of the AHI reduction. Proposed mechanisms for the residual effect include: - **Upper airway fat redistribution:** tirzepatide may preferentially reduce visceral and pharyngeal fat deposits that narrow the airway - **GLP-1 receptor brainstem signaling:** preclinical research finds GLP-1 receptors in the nucleus tractus solitarius, a brainstem region involved in respiratory rhythm control - **Reduced nocturnal fluid redistribution:** less fluid shifts from legs to the neck during sleep with reduced body mass - **Anti-inflammatory pathways:** tirzepatide reduces systemic markers like CRP and IL-6, which are elevated in OSA and may contribute to pharyngeal inflammation and muscle dysfunction The weight-independent hypothesis remains unconfirmed — it’s mechanistically plausible, but no trial has yet separated these effects definitively. The research direction is promising, not conclusive. ## Finding 3 — Patient-Reported Outcomes: Better Sleep and Less Daytime Impairment A 2025 follow-up analysis published in _Sleep Medicine_ examined patient-reported outcome measures (PROMs) from SURMOUNT-OSA participants. This mattered because AHI is objective — but how people actually feel is a distinct dimension of sleep apnea burden. Tirzepatide-treated participants reported statistically significant improvements in: - Sleep disturbance (PROMIS-SD scale) - Daytime sleep-related impairment (PROMIS-SRI scale) - General functioning and health-related quality of life The authors concluded that improvements in patient experience tracked closely with objective AHI changes — not just with weight loss. This suggests the treatment’s benefit is meaningful to patients, not only to polysomnography results. Source: [Kanua et al., _Sleep Medicine_ 2025](https://pubmed.ncbi.nlm.nih.gov/40774158/) ## FDA Approval and Regulatory Framing In June 2024, the FDA approved branded tirzepatide (Zepbound, by Eli Lilly) for moderate-to-severe OSA with obesity — making it the first medication ever approved in the US for OSA treatment. This is a meaningful regulatory milestone. Important distinctions for patients exploring options: - **Branded Zepbound:** FDA-approved for OSA with obesity - **Compounded tirzepatide:** Not FDA-approved. Prepared under federal compounding regulations. A separate category legally and clinically. Any use of compounded tirzepatide is subject to medical approval by a licensed provider following individual evaluation. For a deeper look at the compounding pathway, see [how compounded tirzepatide access works via asynchronous telehealth](https://www.telosrx.com/blogs/glp1/compounded-tirzepatide-telehealth-2026). The [SURMOUNT-OSA registration on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05412004) provides the full protocol for researchers and patients who want to review exact eligibility criteria and methodology. ## Gaps the Research Doesn’t Yet Fill Responsible evidence review requires noting what the data doesn’t show: - **Long-term durability beyond 52 weeks:** No published data beyond the trial period - **AHI rebound after stopping:** Weight regain following cessation is well-documented; AHI rebound is the expected consequence, but quantified data are lacking - **Head-to-head vs CPAP:** No randomized trial has directly compared tirzepatide to CPAP for OSA outcomes - **Non-obese patients:** People with BMI under 30 were not studied; results are not generalizable to that population - **Mild OSA:** Only moderate-to-severe OSA (AHI ≥15) was studied If you’re on GLP-1 therapy or considering it, our guide to [managing GLP-1 side effects](https://www.telosrx.com/blogs/glp1/glp1-side-effects-management-research) covers practical considerations. For a side-by-side look at tirzepatide and semaglutide across multiple outcomes, see our [tirzepatide vs semaglutide comparison](https://www.telosrx.com/blogs/glp1/tirzepatide-vs-semaglutide-compounded-glp1-comparison). ## Frequently Asked Questions ### Does tirzepatide help with sleep apnea? Yes — in clinical trials. Two phase 3 randomized controlled trials (SURMOUNT-OSA) showed tirzepatide reduced AHI by 55–62% in adults with moderate-to-severe OSA and obesity over 52 weeks. These results require individual evaluation; they’re not guaranteed for every patient. Any tirzepatide use is subject to medical approval by a licensed provider. ### How much does tirzepatide reduce AHI? In SURMOUNT-OSA, tirzepatide reduced AHI by an average of 27.4 events/hour (no-CPAP cohort) and 30.4 events/hour (CPAP cohort), compared to 4.8 and 6.0 reductions with placebo respectively. Approximately 42–51% of tirzepatide-treated participants achieved AHI below 5, meeting the clinical definition of OSA remission. Individual results vary. ### Can tirzepatide replace CPAP for sleep apnea? No direct comparison trial exists. In SURMOUNT-OSA, roughly 42% of participants in the no-CPAP cohort achieved remission (AHI <5) — but 58% did not. CPAP remains the established standard of care. Any decision to modify CPAP use should be made with a licensed provider based on individual response and monitoring data. ### Is tirzepatide FDA-approved for sleep apnea? Branded tirzepatide (Zepbound, Eli Lilly) received FDA approval in June 2024 for moderate-to-severe OSA with obesity. Compounded tirzepatide is not FDA-approved and is regulated differently. Patients should understand these distinctions before seeking access through any telehealth or pharmacy channel. ### How does tirzepatide improve sleep apnea beyond weight loss? Statistical analyses in SURMOUNT-OSA suggested a residual AHI benefit beyond what weight reduction alone explains. Proposed mechanisms include GLP-1 receptor signaling in brainstem respiratory control centers, reduction of pharyngeal fat deposits, and anti-inflammatory effects. These are plausible hypotheses supported by preclinical data — not confirmed clinical facts. ### Who was studied in the SURMOUNT-OSA trials? Adults with moderate-to-severe OSA (AHI ≥15), obesity (BMI ≥30), and no current GLP-1 use. The trials excluded people with type 1 diabetes, recent major cardiovascular events, severe hepatic or renal impairment, and several other conditions. Results apply most directly to people who match the enrolled population profile. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ Start your private evaluation at [TelosRX](https://telosrx.com). **Tags:** compounded tirzepatide, GLP-1, OSA, sleep apnea, SURMOUNT-OSA, tirzepatide --- > Source: [Telos RX](https://www.telosrx.com/blogs/glp1/tirzepatide-for-sleep-apnea-research)